Dorval Allison
Verve Therapeutics, Inc. · Chief Financial Officer
Dorval Allison is listed in filings as Chief Financial Officer at Verve Therapeutics, Inc.. This profile follows SEC Form 4 activity through Jul 28, 2025, including sale activity. Recent filings connect the profile to Verve Therapeutics, Inc. (VERV) and Puma Biotechnology, Inc. (PBYI). The current snapshot covers public activity from Jun 17, 2024 to Jul 28, 2025. Reported amounts are shown as $3.1K to $1.6M. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.
History Trades
| Company | Value | Action | Price | Last Price |
|---|---|---|---|---|
| $3.1k555 shares | SellDec 2, 2024 | $5.64 | $11.13 | |
| $14k3.4k shares | SellApr 2, 2025 | $4.15 | $11.13 | |
| $37k11k shares | SellJun 13, 2024 | $3.37 | $8.40 |